CDK2-IN-73 | CAS#2079895-42-2 | CDK2 inhibitor

MedKoo Cat#: 562112 | Name: CDK2-IN-73

Description:

WARNING: This product is for research use only, not for human or veterinary use.

CDK2-IN-73 is a potent and highly selective CDK2 inhibitor.

Chemical Structure

CDK2-IN-73

CAS#2079895-42-2

Theoretical Analysis

MedKoo Cat#: 562112

Name: CDK2-IN-73

CAS#: 2079895-42-2

Chemical Formula: C23H18N6O2S

Exact Mass: 442.1212

Molecular Weight: 442.49

Elemental Analysis: C, 62.43; H, 4.10; N, 18.99; O, 7.23; S, 7.25

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

CDK2-IN-73; CDK2 IN 73; CDK2IN73; CDK2 inhibitor 73; CDK2 inhibitor-73;

IUPAC/Chemical Name

4-((6-([1,1'-Biphenyl]-3-yl)-9H-purin-2-yl)amino) benzenesulfonamide

InChi Key

FUGRWXRQJGJIER-UHFFFAOYSA-N

InChi Code

InChI=1S/C23H18N6O2S/c24-32(30,31)19-11-9-18(10-12-19)27-23-28-20(21-22(29-23)26-14-25-21)17-8-4-7-16(13-17)15-5-2-1-3-6-15/h1-14H,(H2,24,30,31)(H2,25,26,27,28,29)

SMILES Code

O=S(C1=CC=C(NC2=NC(C3=CC(C4=CC=CC=C4)=CC=C3)=C5N=CNC5=N2)C=C1)(N)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 442.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Coxon CR, Anscombe E, Harnor SJ, Martin MP, Carbain B, Golding BT, Hardcastle IR, Harlow LK, Korolchuk S, Matheson CJ, Newell DR, Noble ME, Sivaprakasam M, Tudhope SJ, Turner DM, Wang LZ, Wedge SR, Wong C, Griffin RJ, Endicott JA, Cano C. Cyclin-Dependent Kinase (CDK) Inhibitors: Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines. J Med Chem. 2017 Mar 9;60(5):1746-1767. doi: 10.1021/acs.jmedchem.6b01254. Epub 2017 Feb 14. PubMed PMID: 28005359. 2: Gao A, Zhang L, Chen X, Chen Y, Xu Z, Liu Y, Zhu W. Effect of VTCN1 on progression and metastasis of ovarian carcinoma in vitro and vivo. Biomed Pharmacother. 2015 Jul;73:129-34. doi: 10.1016/j.biopha.2015.05.016. Epub 2015 Jun 1. PubMed PMID: 26211593. 3: Fu J, Koul D, Yao J, Wang S, Yuan Y, Colman H, Sulman EP, Lang FF, Yung WK. Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells. Cancer Res. 2013 May 15;73(10):3062-74. doi: 10.1158/0008-5472.CAN-12-2033. Epub 2013 Mar 14. Retraction in: Koul D, Yao J, Wan S, Yuan Y, Sulman E, Lang F, Yung WK, Colman H. Cancer Res. 2014 Nov 15;74(22):6731-2. PubMed PMID: 23492364; PubMed Central PMCID: PMC3655088. 4: William AD, Lee AC, Goh KC, Blanchard S, Poulsen A, Teo EL, Nagaraj H, Lee CP, Wang H, Williams M, Sun ET, Hu C, Jayaraman R, Pasha MK, Ethirajulu K, Wood JM, Dymock BW. Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptaco sa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer. J Med Chem. 2012 Jan 12;55(1):169-96. doi: 10.1021/jm201112g. Epub 2011 Dec 29. PubMed PMID: 22148278. 5: Shi Y, Chen J, Li Z, Zhang Z, Yu H, Sun K, Wang X, Song X, Wang Y, Zhen Y, Yang T, Lou K, Zhang Y, Zhang G, Hu Y, Ji J, Hui R. C10ORF97 is a novel tumor-suppressor gene of non-small-cell lung cancer and a functional variant of this gene increases the risk of non-small-cell lung cancer. Oncogene. 2011 Sep 29;30(39):4107-17. doi: 10.1038/onc.2011.116. Epub 2011 Apr 18. PubMed PMID: 21499297. 6: Cai H, Xiang YB, Qu S, Long J, Cai Q, Gao J, Zheng W, Shu XO. Association of genetic polymorphisms in cell-cycle control genes and susceptibility to endometrial cancer among Chinese women. Am J Epidemiol. 2011 Jun 1;173(11):1263-71. doi: 10.1093/aje/kwr002. Epub 2011 Mar 31. PubMed PMID: 21454826; PubMed Central PMCID: PMC3101066. 7: Heiferman MJ, Salabat MR, Ujiki MB, Strouch MJ, Cheon EC, Silverman RB, Bentrem DJ. Sansalvamide induces pancreatic cancer growth arrest through changes in the cell cycle. Anticancer Res. 2010 Jan;30(1):73-8. PubMed PMID: 20150619. 8: Zhou T, Huang D, Caflisch A. Is quantum mechanics necessary for predicting binding free energy? J Med Chem. 2008 Jul 24;51(14):4280-8. doi: 10.1021/jm800242q. Epub 2008 Jun 25. PubMed PMID: 18578469. 9: Krajewski M, Rothweiler U, D'Silva L, Majumdar S, Klein C, Holak TA. An NMR-based antagonist induced dissociation assay for targeting the ligand-protein and protein-protein interactions in competition binding experiments. J Med Chem. 2007 Sep 6;50(18):4382-7. Epub 2007 Aug 16. PubMed PMID: 17696513. 10: da Silva Morais A, Saliez A, Leclercq I, Horsmans Y, Stärkel P. Inhibition of the Ras oncoprotein reduces proliferation of hepatocytes in vitro and in vivo in rats. Clin Sci (Lond). 2008 Jan;114(1):73-83. PubMed PMID: 17678500. 11: Rakitina TV, Vasilevskaya IA, O'Dwyer PJ. Inhibition of G1/S transition potentiates oxaliplatin-induced cell death in colon cancer cell lines. Biochem Pharmacol. 2007 Jun 1;73(11):1715-26. Epub 2007 Feb 4. PubMed PMID: 17343830. 12: Gupte RS, Traganos F, Darzynkiewicz Z, Lee MY. Phosphorylation of RIalpha by cyclin-dependent kinase CDK 2/cyclin E modulates the dissociation of the RIalpha-RFC40 complex. Cell Cycle. 2006 Mar;5(6):653-60. Epub 2006 Mar 15. PubMed PMID: 16582606. 13: Santos CR, Rodríguez-Pinilla M, Vega FM, Rodríguez-Peralto JL, Blanco S, Sevilla A, Valbuena A, Hernández T, van Wijnen AJ, Li F, de Alava E, Sánchez-Céspedes M, Lazo PA. VRK1 signaling pathway in the context of the proliferation phenotype in head and neck squamous cell carcinoma. Mol Cancer Res. 2006 Mar;4(3):177-85. PubMed PMID: 16547155. 14: Abdulkader I, Sánchez L, Cameselle-Teijeiro J, Gude F, Chávez JE, López-López R, Forteza J, Fraga M. Cell-cycle-associated markers and clinical outcome in human epithelial cancers: a tissue microarray study. Oncol Rep. 2005 Dec;14(6):1527-31. PubMed PMID: 16273250. 15: Li J, Hu W, Baldassare JJ, Bora PS, Chen S, Poulos JE, O'Neill R, Britton RS, Bacon BR. The ethanol metabolite, linolenic acid ethyl ester, stimulates mitogen-activated protein kinase and cyclin signaling in hepatic stellate cells. Life Sci. 2003 Jul 18;73(9):1083-96. PubMed PMID: 12818718. 16: Roublevskaia IN, Haake AR, Ludlow JW, Polevoda BV. Induced apoptosis in human prostate cancer cell line LNCaP by Ukrain. Drugs Exp Clin Res. 2000;26(5-6):141-7. PubMed PMID: 11345020. 17: Kubo A, Nakagawa K, Varma RK, Conrad NK, Cheng JQ, Lee WC, Testa JR, Johnson BE, Kaye FJ, Kelley MJ. The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. Clin Cancer Res. 1999 Dec;5(12):4279-86. PubMed PMID: 10632371. 18: Schüchner S, Wintersberger E. Binding of polyomavirus small T antigen to protein phosphatase 2A is required for elimination of p27 and support of S-phase induction in concert with large T antigen. J Virol. 1999 Nov;73(11):9266-73. PubMed PMID: 10516035; PubMed Central PMCID: PMC112961. 19: Sui L, Tokuda M, Ohno M, Hatase O, Hando T. The concurrent expression of p27(kip1) and cyclin D1 in epithelial ovarian tumors. Gynecol Oncol. 1999 May;73(2):202-9. PubMed PMID: 10329035. 20: Ye M, Duus KM, Peng J, Price DH, Grose C. Varicella-zoster virus Fc receptor component gI is phosphorylated on its endodomain by a cyclin-dependent kinase. J Virol. 1999 Feb;73(2):1320-30. PubMed PMID: 9882337; PubMed Central PMCID: PMC103956.